Login to Your Account



CEO: Interest Starting to 'Catalyze'

Second Genome Inks First Microbiome Pharma Deal

By Jennifer Boggs
Managing Editor

Wednesday, June 5, 2013
Second Genome Inc. brought on board its first big pharma partner, signing Janssen Biotech Inc. to a multiyear deal focused on using the San Bruno, Calif.-based biotech's microbiome modulation platform to discover drugs for ulcerative colitis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription